THE PLATFORM REAL 
DRUG HUNTERS
HAVE BEEN WAITING FOR

AI for medicinal chemistry that actually sees what the protein sees. Find novel candidates, bust competitor patents, profile safety, and plan synthesis, all from your browser.

Founded and built by a medicinal chemist with academic and industry experience across CRO, pharma, and DEL platforms. Built on patented quantum-grade molecular embeddings developed in-house. Internal benchmark methodology available on request.

I watched this kill a company.

Early career. Venture-backed startup.

Promising science. Nervous investors.

The platform was slow. The board wanted a tractable drug program in 90 days.

Fast decisions, real money, real careers on the line.

We had a hit molecule to work from and a clock ticking.

The tools we used to decide which molecules to make next were built for the wrong job.

Our software compared molecules the way a first-year student would.

Count the atoms. Trace the bonds. Compare the pattern.

It could not see what the protein sees.

And the protein is the only thing that actually matters.

The program stalled. The investors left. The company struggled.

I think about it often.

Not because of the outcome.

Because of the gap.

The tools the industry trusts to do this work are blind to the thing that decides whether it works.

Small biotechs die because of this. Quietly.

Continuously.

And nobody talks about it.

Here is the test case that should make you uncomfortable.


Sertraline and Escitalopram.

Two of the most prescribed antidepressants in history.

Same disease. Same target. Same pharmacology.

Every chemist alive would call them cousins.

Your discovery software scores them at 0.08.

Heisenberg (HFP) scores it 0.87.

On a scale where 1 is identical and 0 is unrelated.

The software says they are strangers.

They are not strangers.

They are twins.

The protein sees it immediately.

Your software does not.

This is not a rare case.

This is every lead decision you make.

Every scaffold you greenlit. Every series you killed.

Every compound your team cleared as "novel" because the similarity score was low.

The score that approved the program in month one is the one that kills it in year three.

By the time it fails, nobody remembers the score.
The problem stays invisible.

Which is exactly why it keeps happening.

Heisenberg fixes it.

Paste any molecule into the platform.

We read the full 3D electronic environment.

Shape. Charge. Geometry.

The things the protein actually responds to.

Not the drawing on the page.

Sertraline and Escitalopram?

Standard software: 0.08.

Heisenberg: 0.87.

Across 147 scaffold hop pairs, standard tools average 0.20 similarity.

Heisenberg averages 0.83.

This is not a marginal improvement.

This is the difference between a tool that lets you kill your program and a tool that does not.

This is the tool I needed the year my team's program died.

It did not exist then.

It exists now.

Don't guess. See what the protein sees.

What You'll Unlock:

  • ​See What The Protein Sees: Most similarity tools compare molecules like a 2D drawing. Heisenberg reads the full 3D electronic environment. The difference changes everything.
  • 200 Million Compounds, Real Pharmacological Space: Search a purchasable library of real, orderable molecules ranked by how they actually bind. Not how they look on paper. (included FREE)
  • One-Click Scaffold Hopping: Find molecules that do what your lead does, but sit in a completely different chemical region. The workflow small startups run when they need fresh IP fast.
  •  Generate Novel Candidates In Minutes: From a single lead structure, get back a full portfolio with safety profiling, synthesis routes, and scored hypotheses. All in your browser.
  • ​Scaffold Hop In Minutes, Not Weeks: Find molecules that bind your lead's pocket but sit in completely different chemical territory. The workflow that small biotechs run when they need fresh chemical matter fast.
  • ​Safety Profiling On Every Molecule: Twenty-two predictive endpoints. Toxicity, absorption, metabolism, clearance. Every candidate in every run, automatically.
  • ​Real Synthesis Routes, Not Handwaves: Top candidates come back with working routes, reaction conditions, and starting materials you can actually order.
  • ​Your Data. Your Molecules. Your IP: Full privacy on every paid tier. No query logging. No training on your compounds. Commercial use by default.

Turn Any sentence Into A Working App In Minutes.

Speed Isn't a Luxury Anymore. It's a Survival Skill.

The truth?
Most people will never build what they dream about.

Not because they’re lazy.
Not because they’re stupid.
Because they’re slow.

The second you have an idea, you’re racing against the clock.
Against other founders. Against the market. Against your own doubt.

And 99% of people lose that race before they even realize they’re in it.

The game was rigged against them... until Famous.ai rewrote the rules.

It’s not "another AI tool."
It’s not "no-code for beginners."
It’s not "pretty templates with no soul."

It’s a weapon.
A full-stack, database-backed, revenue-ready, launch-in-hours weapon.

You tell it what you want.
It builds it, for real.

Frontend. Backend. Auth. Billing. Admin Panels.
The invisible work that normally kills dreams before they ever launch? Gone. Done. Handled.

And here’s the scary part: it actually thinks.

It doesn’t just vomit code like the other tools.

It plans. It engineers. It makes decisions the way a grizzled CTO would.

It protects you from mistakes you don’t even know you're about to make.

It builds things you didn’t even realize you needed until you see it, and wonder how you ever lived without it.

While everyone else is stuck googling “how to add payments” you’re deploying.

While they’re arguing over API documentation — you’re closing customers.

One click. Live. Yours.

No rented platforms. No invisible locks.

Every pixel, every function, every keystroke; belongs to you.

And by the time they realize what’s happening?
You're already three releases ahead.
Already in front of their customers.
Already famous for the thing they wish they built first.

But here’s the brutal truth nobody wants to admit:
Speed wins.
Period. Full stop. End of story.

Those who move faster... win bigger.
Those who hesitate... disappear quietly.

Famous.ai doesn’t just give you speed.
It gives you an unfair fcking advantage.

Use it right and you don’t just catch up.
You become the one they’re chasing.

(But fair warning... this window won’t stay open forever.)
The ones who figure it out early will dominate.

Everyone else?
They’ll be left wondering how the hell they got left behind.

The next wave of legends isn’t waiting. They’re building.. faster than you think.

$27/month

cancel anytime

30-Day No Risk Policy

We are confident this changes how you work. If it doesn't, email us within 30 days and we refund you in full. One line of email. No forms. No friction.

Apple or Android Pay will Display here when available.
1
YOUR INFO
2
FINALIZE
NEXT
By clicking 'Next,' you acknowledge that you have read, understood, and agree to our Terms of Service and Privacy Policy. Your subscription to heisenbergbio.com will auto-renew at $27/month. You can cancel anytime from inside the platform.

FREQUENTLY ASKED QUESTIONS

"Does this actually work?"

On our published validation of 24 approved drugs across 12 targets, Heisenberg's 3D pharmacophore fingerprint separates same-target drug pairs from cross-target pairs. 

Full data, SMILES, and code are open.

Our full benchmark is published here.

"How is this different from ROCS, Phase, or Spark?"

Most tools compare flat 2D structures or shuffle fragments from a fixed library.

Heisenberg matches the 3D shape and electrostatics the protein actually binds, and generates new scaffolds outside any library with synthesis routes attached.

Same pharmacology. New IP. In one run.

"Will my chemistry get scraped?"

No. Your molecules never train our models. We don't log your queries.

Everything is encrypted, isolated to your account, and you can delete it on demand.

SOC 2 audit in progress. Security questionnaire available on request.

Your IP stays yours.

"Can I patent the molecules?"

Yes. Novelty is the point.

Every generated molecule can be checked against PubChem, ChEMBL, SureChEMBL, and the USPTO and EPO patent databases.

Anything already disclosed or claimed is flagged with the citation.

You get a clean starting point. Final freedom-to-operate is your patent counsel's call.

"Can these molecules actually be synthesized?"

Yes. Every molecule is checked for chemical validity, scored for synthetic accessibility, and run through retrosynthesis before it reaches you.

Top recommendations arrive with a full synthesis route mapped to commercial starting materials or a direct purchase link if a vendor already stocks the compound.

You can order any molecule in your portfolio.

"Which modalities does it support?"

Small molecules today, validated across kinases, GPCRs, proteases, transporters, ion channels, and metabolic enzymes.

PROTACs, molecular glues, and peptide therapeutics are next on the roadmap.

We are building each modality engine separately rather than shipping a generic version that would underperform on all three.

If your program is in one of those modalities, contact us. We'll add you to the early access list for the one you care about.

"What do I get with Heisenberg?"

Your own dedicated ML engine for drug discovery, wired into a comprehensive molecule registry and ELN.

Generative molecule design from any SMILES. 3D pharmacophore search across our compound library. Scaffold-hop discovery. ADMET prediction. Retrosynthesis routes. Patent intelligence.

One login. One platform. No add-ons.

HEISENBERGBIO.COM
2026 All Rights Reserved.

support@heisenbergbio.com

Hurry! The 59% off discount expires when the timer hits 0...

countdown
00Hours00Minutes00Seconds